Cystatin C (CST3) is a small, secreted cysteine protease inhibitor belonging to the cystatin superfamily of protease inhibitors. Encoded by the CST3 gene located on chromosome 20, cystatin C is a 120-amino acid protein with a molecular weight of approximately 13 kDa. This protein is produced by virtually all nucleated cells and is constitutively present in most body fluids, including blood plasma, cerebrospinal fluid (CSF), and urine. Cystatin C functions as a non-glycosylated, non-disulfide-bonded inhibitor that plays critical roles in regulating proteolytic activity within extracellular compartments. In neurodegenerative diseases, cystatin C has emerged as both a potential biomarker and a molecule with direct neuroprotective properties, making it a subject of intense research in the neurodegeneration field.
Function/Biology
...
Cystatin C (CST3)
Overview
Cystatin C (CST3) is a small, secreted cysteine protease inhibitor belonging to the cystatin superfamily of protease inhibitors. Encoded by the CST3 gene located on chromosome 20, cystatin C is a 120-amino acid protein with a molecular weight of approximately 13 kDa. This protein is produced by virtually all nucleated cells and is constitutively present in most body fluids, including blood plasma, cerebrospinal fluid (CSF), and urine. Cystatin C functions as a non-glycosylated, non-disulfide-bonded inhibitor that plays critical roles in regulating proteolytic activity within extracellular compartments. In neurodegenerative diseases, cystatin C has emerged as both a potential biomarker and a molecule with direct neuroprotective properties, making it a subject of intense research in the neurodegeneration field.
Function/Biology
Cystatin C serves as a potent reversible inhibitor of cysteine proteases, particularly cathepsins B, H, K, L, and S. These proteases participate in normal cellular processes including protein degradation, antigen presentation, and tissue remodeling. By binding to the active site of cathepsins through its inhibitory wedge domain, cystatin C maintains protease homeostasis and prevents excessive proteolytic activity. The protein operates through a tight-binding inhibition mechanism, with dissociation constants typically in the picomolar range. Unlike tissue inhibitors of metalloproteinases (TIMPs), cystatin C specifically targets cysteine proteases rather than metalloproteinases. This inhibitory function is particularly important in the central nervous system, where cystatin C reaches relatively high concentrations in CSF. The protein is continuously synthesized and secreted by various cell types including microglia, neurons, and glial cells, allowing it to maintain dynamic regulation of protease activity in neuronal microenvironments.
Role in Neurodegeneration
Dysregulation of cystatin C and cathepsin activity has been implicated in multiple neurodegenerative diseases. In Alzheimer's disease, altered cystatin C levels in CSF correlate with disease progression and cognitive decline. The protein plays conflicting roles: while normally neuroprotective through protease inhibition, excessive cystatin C can contribute to amyloid-beta accumulation by reducing its degradation through cathepsin-mediated pathways. In Parkinson's disease, cathepsin L activity regulation appears critical for α-synuclein processing, and abnormal cystatin C levels may contribute to pathological α-synuclein aggregation. Genetic mutations in CST3 cause hereditary cerebral amyloid angiopathy (HCAA), an autosomal-dominant disorder characterized by amyloid-beta deposition in cerebral blood vessels, leading to early-onset dementia and intracerebral hemorrhage. In amyotrophic lateral sclerosis (ALS), cystatin C expression changes in affected tissues suggest involvement in motor neuron degeneration mechanisms. The protein may also influence neuroinflammation through microglial regulation, as activated microglia express altered cystatin C levels during neurodegeneration.
Molecular Mechanisms
Cystatin C modulates neurodegeneration through multiple interconnected mechanisms. Cathepsin inhibition by cystatin C prevents excessive lysosomal protease activity, which can damage cellular components if dysregulated. In autophagy-related processes, appropriate cystatin C levels maintain balanced cathepsin activity needed for proper autophagic flux. The protein interacts with amyloid-beta through mechanisms independent of cathepsin inhibition, potentially affecting amyloid clearance and aggregation kinetics. Mutant cystatin C variants associated with HCAA show increased tendency toward polymerization and amyloid fibril formation, promoting vascular amyloid-beta deposition. Cystatin C also modulates neuroinflammatory responses by influencing cathepsin-mediated processing of pro-inflammatory cytokines and chemokines. The protein's presence in extracellular vesicles and exosomes suggests involvement in cell-to-cell communication mechanisms relevant to neurodegenerative pathology spreading.
Clinical/Research Significance
Cystatin C serves as a validated CSF biomarker with diagnostic and prognostic potential in neurodegenerative diseases. Abnormal CSF cystatin C levels are associated with amyloid-beta and tau pathology in Alzheimer's disease and may help identify prodromal disease states. The protein represents a therapeutic target, with research exploring both protease inhibition enhancement and interventions to restore normal cystatin C levels. Understanding HCAA mutations has illuminated fundamental mechanisms of amyloid-beta metabolism relevant to sporadic Alzheimer's disease.
Related Entities
Cathepsin B, L, S - primary protease targets of cystatin C
Cystatin A, B, F - related cysteine protease inhibitors
Amyloid-beta - protein influenced by cystatin C-regulated proteolysis